





RELEASING THE BRAKES: STRATEGIES TO REMODEL THE TUMOR 










A dissertation submitted to Johns Hopkins University in conformity with the 
requirements for the degree of Doctor of Philosophy 
 
Baltimore, Maryland 




The tumor immune infiltrate and tumor cytokine microenvironment have been 
shown to be crucially important to patient responses to immunotherapy. The presence of 
effector T cells in the tumor correlates highly with good disease prognosis, while the 
presence of regulatory and inhibitory cell subsets and cytokines predicts poor outcomes.  
Thus, the ability to manipulate the cellular infiltrate and cytokine presence within the 
tumor microenvironment (TME) represents an important step forward in initiating 
productive responses against tumors. Here we employ several vaccination strategies and 
molecular methods to activate anti-tumor immunity, increase tumor immune infiltration, 
and skew the cytokine environment of tumors, all with the goal of creating durable and 
curative immune responses. We show that an attenuated strain of Listeria Monocytogenes 
(LM), engineered to express the tumor antigens TRP-2 and GP-100, has moderate 
efficacy in activating lymphocytes, increasing immune infiltrate, and reducing tumor 
burden. However, when this vaccine is combined with the checkpoint blockade antibody 
aCTLA4-IgG2a, immune infiltration and tumor control increases greatly. These effects 
are dependent on the ability of aCTLA4-IgG2a to bind Fc receptors and reduce the 
percentage of CD4+ cells that are FoxP3+. Lastly, we utilize the the STING agonist 
ADU-S100, a modified cyclic-di-adenosine molecule, henceforth referred to as cyclic 
dinucleotide (CDN), to induce innate effector cytokines like GM-CSF, IL-1b, IFNb, and 
TNFa. Intratumoral administration of CDN leads to TNFa-dependent tumor necrosis and 
clearance of established tumors. We explore the acute mechanism of CDN action and 
find that both immune and stromal cells play critical functions by sensing STING, 
producing cytokines, and modulating the tumor microenvironment. Interestingly, stromal 
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cell CDN sensing seems to be indispensable for achieving acute tumor necrosis by CDN 
injection. All of the above methods represent potential clinical targets to manipulate the 
TME and increase immune infiltrate to achieve better responses, and the underlying 
molecular mechanisms are important to understand as we go forward exploring the next 
generation of therapeutic targets and vaccines.  
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The following body of work represents an attempt to more fully understand the 
mechanisms behind a few important cellular and molecular components of the immune 
system as they pertain to tumor immunology. It was performed not only over the course 
of many years, but over the course of maturation from student to scientist. With these 
experiments, comes the full understanding of legitimate differences between mouse and 
human systems, but also with the knowledge that a greater understanding of the former 
leads to the ability to translate to the later. The joy of scientific research is the ability to 
ask an important question at the beginning of the day, and by the end of the day answer it 
of your own volition. The difficulty of research is spending months or years dedicating 
your time and emotion into answering questions, only to come up with dissatisfying 
answers. Both have happened over the course of these projects, but never once will I say 





As I have discovered over the past 5 years, there are many factors that play a part 
in earning a Ph.D. and writing a thesis. My own volition was but a small part. This thesis 
is dedicated foremost to my family, without whom I would not have the drive for 
excellence. From an early age, my parents demanded I strive to exceed in academic areas, 
and that has made all the difference. To my brothers, our closeness has been a great 
comfort, your ridiculous achievements have set a high bar for me to look up to, and 
particularly to Joe, who introduced me to the idea and field of medical research. Lastly, to 
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Tumor immunology, immune editing, and vaccination 
Since the late 1800’s, anecdotal evidence linking infection and the regression of 
tumor masses has been recorded. However, in 1891, William Coley, a surgical 
oncologist, began injecting Streptococcus bacteria directly into tumor masses and 
observed gradual decrease in tumor burden in some masses1.   Coley’s basic experiments 
are the first examples of immunotherapy in humans, but were not understood to be so at 
the time. Similarly, over the past 50 years, physicians have observed an increase in 
incidence of cancer in patients who are immunosuppressed. Patients undergoing 
transplant surgery and kept on immunosuppressive agents, or those with immune 
suppressive infections like HIV all have higher incidences of cancer2,3. Based on these 
observations, in the past two decades, dedicated tumor immunologists have begun to 
study the intricate mechanisms that regulate immune activation and tolerance to bacteria, 
viruses, parasites, cancers, and indeed any pathogen that threatens the integrity of our 
body.   
The first studies to define immune system’s regulation of cancers utilized MCA- 
induced sarcoma in animals with a competent immune system (WT), or in animals 
without T cell and B cells (RAG-/-). Once grown, the tumors from WT and RAG-/- mice 
were reinjected into WT or RAG-/- animals. Interestingly, all tumors grew normally 
except those raised in a RAG-/- animal and reinjected into a WT animal, which grew a 
dramatically reduced rate4. This experiment highly suggested that tumors raised in 
animals with an immune system were somehow shaped by the presence of that immune 
system to escape future encounters, while tumor raised in animals with no immune 
system encountered no such pressure, and thus were slowed by the immune system when 
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they experienced it. This work introduced the idea of immune selection and evasion by 
tumors, and solidified the idea that the immune system plays a key role in the shaping 
and elimination of cancer.  
The most basic tool of an immunologist is the vaccine. A vaccine is quite simply 
any combination of molecule, compound, or organism that activates the immune system 
to kill a specific target. These targets molecularly are short amino acid peptides called 
epitopes, and thus many vaccines consist of two molecular parts, an adjuvant that 
activates immune cells, and peptide that grants it specificity. Vaccination to elicit an 
antibody response has been resoundingly successful, as many common vaccines to 
control viral and bacterial infections like Measles, Tetanus, Polio, and smallpox have 
virtually eradicated the effects of those diseases or the actual pathogens themselves. 
Tumor vaccines generally aim to enhance a cellular CD8+ response and have shown 
relatively disappointing clinical efficacy. Thus, the thrust of immune oncology has been 
to gain a more thorough understanding of the immune system to create successful 
vaccination strategies in a directed manner.  
CD8+ Tcells and Target Killing 
The immune system has many components, both cellular and acellular. The CD8+ 
T cell, or cytotoxic T cell, is capable of recognizing and killing stressed or infected cell in 
the body through recognition of cognate antigen as presented by the major 
histocompatibility complex (MHC).  Once an immune response is initiated by infection, 
dendritic cells (DC) migrate from the site of insult to the draining lymph node, where 
mature CD8+ cells await activation.  At the immune synapse, the localized area of 
contact between a dendritic cell and a CD8+ cell, there are an abundance of molecules 
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that have the capability of activating, inactivating, and otherwise shaping that cells 
activity to a pathogen5. Activation molecules on the DC surface like CD80/CD86, CD70, 
and OX40L bind to their cognate receptors on CD8+ cells (CD28, CD27, and OX40) to 
initiate downstream activation pathways6-10. On the other hand, there are also many 
markers on dendritic cells that can regulate a t cell response. Molecules like PD-L1 can 
lead to a dampening of CD8+ activity, and eventually T cell quiescence or exhaustion11-
14.  This event where a DC activates a CD8+ Tcell is called priming or activation.  This 
initiates a signaling cascades to allow the cell to replicate, become motile, and most 
importantly, to produce effector cytokines like granzyme B, interferon Gamma, TNFa, 
and IL-2. Recently it has been suggested that multifunctional T cells, cells that can 
produce multiple cytokines rather than only one, represent the population of cells that are 
highly effective at carrying out their function15. Once a CD8+ cell has become activated 
by a dendritic cell in the draining lymph node, it then mobilizes to the site of insult.
 At this site, in the absence of overwhelming immunosuppressive modulators (see 
below), the CD8+ cell can begin killing target cells.  
T regulatory Cells   
The immune system employs several mechanisms to regulate the killing activity 
of CD8+ cells. The T regulatory cell (Treg), as it’s name suggests, develops from the 
CD4+ T cell lineage and plays an important role in suppressing the activity of CD8+ T 
cells16. Treg are defined by the transcription factor FoxP317, and by the surface markers 
CD4 and CD2518.  In the absence of Treg and other immunosuppressive mechanisms, 
severe autoimmune diseases can occur19. There are several proposed mechanisms for how 
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Treg may suppress, including suppressive cytokine generaion20, sequestration of 
activating cytokines21, and dendritic cell suppression or inactivation22-24.  
Tregulatory cells are generally thought to develop in two different manors. 
Natural Treg are thought to develop during Tcell maturation in the thymus if the T cell 
recognizes self antigen during what may otherwise be considered negative selection25. 
Induced Treg may develop in the periphery when they experience TGF-b and retinoic 
acid during their activation or possibly at any time during a CD4+ T cell’s life26,27.  
Clinically, Tregulatory cells have become the subject of much focus in tumor 
immunology. The depletion of Tregulatory cells from the tumor microenvironment can 
aid in the restoration of effective immune mediated killing. 28-32  
Anergy and Immune checkpoints 
The immune system is capable of complete and sterilizing immunity when it 
detects a foreign pathogen and mounts a response to it. However, due to the potency of 
the response generated, the immune system also utilizes a variety of mechanisms to 
prevent the generation of immune responses to self-proteins.  One such mechanism, T 
cell tolerance, is the phenomenon through which self-reactive T cells are regulated, and is 
largely mediated by the induction of anergy or deletion.  While many of the mechanisms 
that dictate which of these outcomes occur in vivo remain unclear, some in vitro 
experimental systems have uncovered several of the requirements for the imposition of 
anergy, including the absence of costimulatory signals 33and the expression of checkpoint 
proteins 34,35. Recently, prolonged expression of the intracellular transcription factors 
EGR2 and EGR3 have been shown to enforce the anergy on CD4+ T-cells, supporting the 
hypothesis that anergy is an independently programmed and maintained state for T cells 
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36-39.  Similar to CD4 T-cells, CD8 T cells have also been found to express EGR2 in 
tolerizing environments, though its exact role in these circumstances is not fully 
understood. 
Immune checkpoint molecules are one class of regulatory molecules that modify 
Tcell-Tcell interactions, Tcell-APC interactions, and T cell- Target interactions by 
blocking receptor binding or by preventing downstream signaling through those 
receptors. One of the hallmark extracellular proteins associated with anergy is 
Programmed Death 1(PD-1). PD-1 is an inhibitory checkpoint molecule that, upon 
ligation with its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), negatively regulates the 
function of CD4+ and CD8+ T-cells 40,41. PD-1 signals through an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) that results in the recruitment and activation of the 
phosphatase SHP-2, which in turn, is thought to inhibit TCR signaling through its 
phosphatase activity42. PD-1 ligation has been shown to play a role in T-cell anergy in 
cancer models, as PD-1 -/- mice often have reduced tumor burden when compared to 
their wild type counterparts43. Furthermore, in preclinical models of melanoma, 
fibrosarcoma, colon carcinoma, breast carcinoma, and several other types of tumors, 
monoclonal PD-1 blockade results in tumor control and regression13,44. Reduction in 
tumor burden in these models often correlates with increased tumor infiltration by 
immune cells along with increased effector cytokine production by CD4+ as well as CD8+ 
T-cells. Similarly, blocking PD-1 in the clinic with a monoclonal antibodies directed at 
either PD-1 or its ligand, PD-L1, has recently been demonstrated to increase overall 
survival either alone45, or in combination with another checkpoint blockade, CTLA-4 46. 
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Cytotoxic lymphocyte antigen 4, or CTLA-4, is a key negative regulator of 
immune activation47.  It prevents B-7:CD28 ligation by binding B-7 with a higher avidity 
than CD28, thus sequestering it48 and CTLA-4 ligation has been shown to prevent 
cellular proliferation and induce anergy in vivo34.   While cell surface expression of 
CTLA-4 in many cell types is regulated intracellularly, activated Teffector cells, 
Tregulatory cells, and tumor cells may all express surface CTLA-449-51. However, our 
group and others have shown that  Tregulatory cells, especially those infiltrating the 
tumor, express CTLA4 at 10-100 times the level of other immune cells52. CTLA-4 
blockade with monoclonal antibodies has shown efficacy in pre-clinical models, perhaps 
because aCTLA4 antibodies have been shown to specifically deplete adoptively 
transferred tumor Tregulatory cells through antibody dependent cellular cytotoxicity 
(ADCC)31. Interestingly, experimentation examining non-transferred endogenous 
populations of Treg do not observe a decrease in absolute number, but rather a reduction 
in Treg as a percent of TIL32,52. 
The STING Pathway 
The immune system is evolutionarily primed to prevent infection through the 
possession of receptors for molecules that are common and necessary to viral and 
bacterial existence and replication. These Pattern Recognition Receptors (PRRs) bind 
pathogen associated molecular patterns (PAMPs), and are essential to initiate innate 
immune responses53-55. The ensuing integration of danger signals into innate immune 
signal circuits results in downstream transcription of innate effector molecules such as 
Interferon-b, TNFa, and IL-156. These effector molecules then allow the stromal and 
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immune cells of the body to respond by a variety of reactions including MHC expression, 
an unfolded protein response, or apoptosis.  
One such receptor for danger signals is cyclic GMP-AMP synthase (cGAS). 
cGAS catalyzes the conversion of dsDNA into cyclic dinucleotides (CDN)57-59. CDN in 
turn, bind to an er-resident protein stimulator of interferon Genes (STING) 60,61. In the 
presence of bound CDN, STING dimerizes and phosphorylates the adaptor protein 
TBK1, which can in turn phosphorylate IRF-3 and initiate the transcription of type 1 
interferons61-64.  Additionally, STING ligation induces NF-kB signaling that leads to the 
transcription of TNFa.  
Evolutionarily, the cGAS-STING pathway may have developed for several 
reasons.  The obligate intracellular bacteria Listeria Monocytogenes produces CDN as a 
natural metabolic byproduct, and sensing of CDN intracellularly allows for more efficient 
clearance of the infection65,66. More recently, STING has been implicated in the initiation 
of immune responses to dsDNA viruses such as gamma herpes virus, polio, and HIV57,67-
73, and the discovery that CDN can be shared between cells via gap junctions to prevent 
the spread of virus to neighboring cells solidifies CDN as a major viral defense 
mechanism74,75. Interestingly, the receptor has also been shown to have 
immunosuppressive effects through recruitment of tolerogenic mechanisms63,76,77. 
Stromal Cells 
The innate system is not sourced solely by bone marrow derived cells that do not 
need to rearrange genome for receptor production and diversity, but also by every cell in 
the body that is able to sense danger signals and produce cytokines. The vast majority of 
cells in the body have the ability to recognize cellular damage through nod like receptors, 
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cyctosolic DNA receptors, viral RNA receptors, as well as general mechanisms that allow 
for a cell to become immunogenic after stress or death78. Many of these cells, such as 
endothelial cells, epithelial cells, and especially pseudo-immune cells like tissue resident 
macrophages and microglial cells have the capacity to produce immune cytokines after 
danger signals are sensed79-81. In this way, the stroma is perhaps one of the most crucial 

















B16F10 and CT26 were acquired from ATCC (CRL-6475, and CRL-2639 
Respectively) and were cultured in Complete RPMI (10%FBS, 100u/ml penicillin, 
100ug/ml streptomycin, 250ng/ml amphotericin, 1mM sodium pyruvate, NEAA).  
Mice 
C57BL/6 mice (6-8 week old female) were purchased from Jackson Laboratories 
and BL6-CD45.1 mice (6-8 week old female) were purchased from Charles River.FoxP3 
DTR mice were a gift from Dr. Drew Pardoll and FcgR-/-  (B6.129P2-Fcer1gtm1RavN12) 
breeder mice were purchased from Taconic and bred in Johns Hopkins Facilities. cGAS-/- 
animals were a gift from Skip Virgin. STING-/- animals are the Golden Ticket strain, and 
were a gift from Young Kim. Rag2-/- animals were a gift from Jonathan Powell. IFNar-/- 
(B6.129S2-Ifnar1tm1Agt/Mmjax), TNFa-/- ( B6.129S-Tnftm1Gkl/J), and IL-6-/- 
(B6;129S2-Il6tm1Kopf/J) breeder pairs were purchased from Jackson laboratories and 
bred in Johns Hopkins Facilities. All mouse procedures were approved by the Johns 
Hopkins University Institutional Animal Care and Use Committee and were compliant with 
the Guide for the Care and Use of Laboratory Animals (8th ed. The National Academic 
Press. 2011). 
Chimeric animals were made by irradiating 6-12 week old animals with 2 doses of 
6 gy separated by 3 hours. 3 hours after the second dose of irradiation, mice were 
reconstituted with 5-10 million cells of unirradiated donor bone marrow via tail vein 
injection and left to rest for at least 6 weeks. All chimeric animals were put on uniprim 
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feed at least 1 week before irradiation and removed from uniprim feed at least 1 week 




Therapeutic antibodies aCTLA-4 IgG1 (9D9), aCTLA-4 IgG2a (9D9), aPD-1 
(4H2), anti-DT mIgG1 (1D12) and anti-DT mIgG2a (1D12) were acquired in collaboration 
with Alan Korman and Mark Selby at Bristol-Myers Squibb.  Dosing per injection was 200 
ug for all antibodies, administered IP in 200ul PBS. 
Immunohistochemistry antibodies included CD3 (SP7), ThermoScientific; CD4 
(1), SinoBiological; FoxP3(D608R), Cell Signaling.   
Flow cytometry staining antibodies included CD4-Pacific orange (RM4-5) 
Invitrogen; CD4-FITC (GK1.5), CD8-PerCP/Cy5.5 (53-6.7), CD44-Pacific Blue (IM7), 
CD11b-AlexaFluor700 (M1/70), CD11c-FITC (N418), F4/80-Pe/Cy7 (BM8), 
CD16.2(FcRIV)-PE (9E9), FoxP3-APC (FJK-16s), CD25-PerCp/Cy5.5 (PC61), CTLA4-
PE (UC10-4B9), CD86-PE/Cy5 (GL-1), IFN-gamma-PE/Cy7 (XMG1.2),CD45-BV605 
(30-F11), IFNy-APC(XMG1.2), Gzb-Pacific Blue (GB11),  BioLegend; GranzymeB-PE 
(16G6), CD4-PerCP Cy5.5 (RM4-5), Viability Dye- APC-Cy7, CD8-FITC (53-6.7), 
CD44-AF700 (IM7), TNFa-PE (MP6-XT22), eBioscience; TNF-APC (MP6-XT22), BD 
Biosciences; IL-2-PE-CF594 (JES6-5H4), BD Horizon.  
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Depletion antibodies aCD4 (GK1.5) and aCD8 (2.43) were obtained from Bio X 
Cell. Dosing for depletion antibodies was 200ug IP in 200ul PBS on day -3,-1, +1 relative 
to vaccination, then every 7 days thereafter until completion of the experiment.  
For CDN studies antibodies used included CD11b-AF700 (M1/70), CD44-Pacific 
Blue (IM7), CD11c-FITC (N418), CD86-PE (GL-1), CD19 PerCP-Cy5.5 (6D5), Ly6C-
BV605(HK1.4), CD45.2- APC (104), IA/IE- PerCP-Cy5.5 (M5/114.15.2), Ly6G- BV421 
(1A8), CD16/32-BV510 (93), F4/80-PE-Cy7 (BM8), CD206-BV711 (C068C2), Ly6c- 
PerCP- Cy5.5 (HK1.4), and CD4- BV605 (GK1.5), Biolegend; NOS2-APC (CXNFT), 
NK1.1-PE (PK136), and CD8-PE-Cy7 (53-6.7), EBiosicence; CD4-Pacific Orange (RM4-
5), Life Technologies; CD45.1-FITC (A20) BD Pharmingen. 
LM/2a Tumor Outgrowth and Infiltration Studies 
5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. On day 5, mice were vaccinated via the tail vein with Listeria or given sham treatment. 
On days 5, 7, and 9, mice were given 200ug (in 200ul PBS) of blockade antibodies or PBS 
alone. On day 18 mice were sacrificed. Tumor volume was calculated by the following 
equation: (Length*Width^2)/2. Cell number of spleen and lymph node were counted on a 
hemocytometer while cell numbers of tumor infiltrate were acquired by flow cytometry. 
For Cytokine intracellular staining, animals sacrificed and tumors were harvested 10 days 
after implantation. Whole tumor suspension was incubated with PMA and Ionomycin for 
4.5 hours. Cells were fixed for 30 minutes in Fixation/Permeablilization buffer by BD 
Bioscience (Cat. No. 554714 and 554715) before proceeding to stain.  
CDN Tumor Outgrowth and Infiltration studies 
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5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. Tumors were monitored until the group average was ~80mm^3 and then treated with 
100ug injections of CDN in 40ul PBS or PBS alone every other day for a total of three 
treatments. For chimera studies, a surplus of mice were implanted tumor, then when tumors 
were palpable, animals were selected and groups normalized to ~80mm^3. Tumor 
outgrowth volume was measured by the equation V=1/2(width^2*length). 24 hours after 
treatment, some mice were sacrificed for tumor infiltrate studies by flow cytometry or for 
tumor lysate. Tumor lysate was made by resecting tumors and dissociating in Cell Lytic M 
(Sigma Cat no. C2978) with Protease Inhibitor Cocktail (Sigma S8820).   
 
Cytokine Array 
Blood serum was collected by cheek bleed on days 8 and 11, then by incision of 
the IVC on day 14. Blood sat to clot for 10 minutes then was centrifuged and serum was 
harvested. The Luminex Biorad Mouse Group 1 23-plex assay (#M60-009RDPD) was 
conducted following vendor guidelines. Serum samples were diluted 1:4. Standard curves 
were generated and within the normal ranges expected with the exception of a reduced 
range for GMCSF. IL-4 was not detected.  
Elisa: 
Elisas were purchased as kits as follows:  Mouse IL-1b/IL-1f2 (Catalog No. 
MLB00c), Mouse GM-CSF (Catalog No. MGM00), Mouse IL-6 (Catalog No. M6000B), 
Mouse TNF-a (Catalog No MTA00B) R&D; VeriKine Mouse IFNb Elisa (Catalog No 
15 
 
42400-2) PBL Assay Science; Mouse Inflammatory Cytokines Multi-anylite ELISArray 
Kit (MEM004a), Quiagen.   
Statistics: 
Staticstical significance for bar graphs was determined with a one-sided or two 
sided non-Paired students T test (*=P<.05, **=P<.001, ***=P<.0001). Statistical 
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At the onset of an immune response, many molecular interactions determine the 
magnitude and character of the immune response82. Immune checkpoints like PD-L1 
expressed on dendritic cells, macrophages, and tumor cells, as well as CTLA4, PD-1, and 
Lag-3 expressed on Tcells, can blunt an immune response through ligation of their 
cognate receptors35,40,83. This ligation can promote the dephosporylation of the Tcell 
receptor signaling complex through the recruitment of phosphatases like SHP-2 or block 
interactions with costimulatory molecules  84-86. Cytokines in the immune 
microenvironment like TGF-b and IL-10 can also dampen the immune response by 
activating pathways to suppress production of effector cytokines by Tcells87,88.  Tcells 
activated in, or experiencing these conditions become less effective in their killing 
functions, adopt a tolerized and anergic phenotype, and thus become unable to control 
tumor outgrowth43. However, reversal of this suppressive environment is possible 
through depletion of tolerogenic cell types, checkpoint blockade antibodies, and 
vaccination32,89-91.  
One such vaccine that has gained popularity is engineered attenuated Listeria 
Monocytogenes. Indeed, a combination GVAX+ Listeria vaccine showed a survival 
advantage over GVAX alone in pancreatic cancer patients.92Unaltered, Listeria is an 
obligate intracellular pathogen that preferentially infects liver and can be associated with 
liver toxicity93. However, with targeted deletion of select genes, attenuated variants of 
Listeria have been generated that offer the same adjuvant activity with dramatically 
reduced toxicity93. Listeria is also unique in its activation of the immune system by its 
production of the metabolic byproduct cGAMP, a molecule that has recently been 
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spotlighted for its potential in intratumoral adjuvant therapy65,66,94-96. Additionally, listeria 
outperforms other engineered vaccine platforms as a stimulator of effective CD8+ t cell 
responses due to its preferential infection of CD8+ Dendritic cells, that produce soluble 
factors which lead to antigen specific activation without upregulating the co-inhibitory 
marker PD-1 (unpublished data). Preclinical models have shown that Listeria or 
checkpoint blockade can aid in reduction of tumor burden, but our study differs in that we 
combine two novel strategies (LM-MEL and aCTLA4 IgG2a), observe efficacy in the 






Chapter Specific Materials and Methods 
Cell Lines 
B16F10 and CT26 were acquired from ATCC (CRL-6475, and CRL-2639 
Respectively) and were cultured in Complete RPMI (10%FBS, 100u/ml penicillin, 
100ug/ml streptomycin, 250ng/ml amphotericin, 1mM sodium pyruvate, NEAA).  
Mice 
C57BL/6 mice (6-8 week old female) were purchased from Jackson Laboratories 
and BL6-CD45.1 mice (6-8 week old female) were purchased from Charles River. All 
mouse procedures were approved by the Johns Hopkins University Institutional Animal 
Care and Use Committee and were compliant with the Guide for the Care and Use of 
Laboratory Animals (8th ed. The National Academic Press. 2011). 
Antibodies 
Therapeutic antibodies aCTLA-4 IgG1 (9D9), aCTLA-4 IgG2a (9D9), aPD-1 
(4H2), anti-DT mIgG1 (1D12) and anti-DT mIgG2a (1D12) were acquired in collaboration 
with Alan Korman and Mark Selby at Bristol-Myers Squibb.  Dosing per injection was 200 
ug for all antibodies, administered IP in 200ul PBS. 
Depletion antibodies aCD4 (GK1.5) and aCD8 (2.43) were obtained from Bio X 
Cell. Dosing for depletion antibodies was 200ug IP in 200ul PBS on day -3,-1, +1 relative 
to vaccination, then every 7 days thereafter until completion of the experiment.  
LM/2a Tumor Outgrowth and Infiltration Studies 
5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. On day 5, mice were vaccinated via the tail vein with Listeria or given sham treatment. 
20 
 
On days 5, 7, and 9, mice were given 200ug (in 200ul PBS) of blockade antibodies or PBS 
alone. On day 18 mice were sacrificed. Tumor volume was calculated by the following 
equation: (Length*Width^2)/2. Cell number of spleen and lymph node were counted on a 
hemocytometer while cell numbers of tumor infiltrate were acquired by flow cytometry. 
For Cytokine intracellular staining, animals sacrificed and tumors were harvested 10 days 
after implantation. Whole tumor suspension was incubated with PMA and Ionomycin for 
4.5 hours. Cells were fixed for 30 minutes in Fixation/Permeablilization buffer by BD 
Bioscience (Cat. No. 554714 and 554715) before proceeding to stain.  
Statistics: 
Staticstical significance for bar graphs was determined with a one-sided or two 
sided non-Paired students T test (*=P<.05, **=P<.001, ***=P<.0001). Statistical 





Combination therapy with LM-M/aCTLA4-IgG2a dramatically reduces B16F10 
tumor burden. 
Due to promise generated by recent immunotherapy clinical trials, we sought to 
design a vaccination strategy that affords the best tumor survival advantage in the highly 
aggressive mouse melanoma model B16F10. We employed a novel vaccine, an 
engineered listeria monocytogenes bacteria (LM) that expresses two melanoma antigens 
shared between mouse and human, TRP-2 and GP-100, and combined it with checkpoint 
blockade antibodies, administered at 0, 48, and 96 hours after vaccination (Figure 3-1a). 
Administering this vaccine on its own reduced tumor burden in mice somewhat, though 
not robustly (Figure 3-1b). We hypothesized that addition of checkpoint blockade 
antibodies would release the immunosuppressive environment of the tumor and aid in 
tumor clearance. Somewhat surprisingly, PD-1 blockade conferred no significant 
reduction in tumor burden, so we altered the vaccination strategy to a different 
checkpoint blockade target, CTLA-4. Previous publications have shown that CTLA-4 
blockade enhances T cell activation and may even increase de novo T cell activation99. 
With this knowledge we treated mice with two different aCTLA-4 monoclonal 
antibodies,  aCTLA-4-IgG1 (hereon referred to as non-depleting or ND ) and aCTLA-4-
IgG2a (hereon referred to as Depleting or D).  aCTLA-4 (ND) has relatively little effect 
with or without the addition of LM vaccination. Alternatively, aCTLA-4 (D) 
administration greatly reduces tumor burden as a monotherapy and, with the addition of 
LM, the combination therapy shows remarkable efficacy in this highly aggressive model 
(Figure 3-1b and Figure 3-2). Eventually, B16F10 tumor bearing animals do succumb to 
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tumor burden, but the combination therapy of LM/aCTLA-4 (D) roughly doubles the 
survival time of these animals from ~25 days to ~50 days (Figure 3-2b).  We then 
repeated these experiments in the lymphoma line EL-4 OVA and achieved similar results 
(Data not shown) EL-4 OVA responds to LM-OVA as a monotherapy with significant 
but non-curative effects. However, the addition of aCTLA-4 to this therapy results in the 
depletion of Tregulatory cells from the tumor environment as well as the clearance and 
long term survival of the majority of these animals. 
 
CD4+ and CD8+ cells are negative and positive regulators of tumor clearance, 
respectively. 
Due to now overwhelming data suggesting that CD8 cells directly kill tumor cells 
in vivo,  we depleted CD4+ and CD8+ subsets in mice by administering the antibodies 
GK1.5 (aCD4) and 2.43 (aCD8) on days -3 and -1 before vaccination, as well as every 7 
days therafter. Administration of these antibodies allows for near complete depletion of T 
cells to <0.1% by peripheral blood measurement. Depletion of CD8+ cells from the 
animal dramatically reduces the ability of the combination therapy LM+aCTLA-4 (D) to 
control tumor (Figure 3-3b). Any remaining vaccination advantage may be due to CD8- 
effector subsets such as natural killer cells. Surprisingly, depletion of CD4+ cells after 
combination treatment does not diminish the effect of immune killing, but rather 
enhances it (Figure 3-3c). This suggests that any enhancement of CD8+ cell killing by 
CD4+ conventional cells is overshadowed by the effect of more efficient depletion of 
CD4+ Tregulatory cells by GK1.5. This supports our previous experimentation that has 
shown the effects of Treg in the tumor to be a main controlling characteristic for tumor 
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outgrowth. Similarly, tumor outgrowth in mice vaccinated with LM and treated with 
GK1.5 mirrors tumor outgrowth in mice treated with LM-M and aCTLA-4 (D), 
reinforcing our hypothesis that the main effect of aCTLA-4 (D) is to effectively deplete 
tumor infiltrating Treg, and that differences in the treatment effects between IgG1 and 
IgG2a isotypes are due to differences in the efficiency of Treg depletion. Lastly, 
administration of both GK1.5 and 2.43 antibody has the same effect as administering 2.43 
antibody alone, further suggesting that CD8 mediated killing is essential for tumor 











Figure 3-1: Engineered Listeria Melanogaster vaccine leads to significant 
survival advantage when combined with CTLA4- IgG2a. (A) Schematic of 
experimental design. 10^5 B16F10 tumor cells were implanted in the flank of 
mice on day 0. On Day 5, animals were vaccinated intravenously with LM-MEL. 
On day 5,7,9, animals were administered checkpoint blockade or isotype control 
antibodies via IP injection. (B) Tumor outgrowth curves of treated animals. 
Curves are representative of 3 experiments with 5+ animals per experiment. 
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Figure 3-2:  Engineered Listeria Melanogaster vaccine leads to significant 
survival advantage when combined with CTLA4- IgG2a. (A) Spaghetti plots of 
tumor growth in individual mice for the experiment in Figure 3-1. B) Kapplan-
Meier curve of mouse survival for experiment in (B). Mice were sacrificed when 
tumors reached >2000 mm^3. Curves are representative of 3 experiments with 
5+ animals per experiment. 
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Figure 3-3: CD4 depletion enhances treatment effect through Treg depletion, but 
only in the presence of CD8+ cells. (A-D) Mice were treated with 200ug 
aCD4(GK1.5), aCD8(2.43), or both antibodies on day -3 and -1 before 
vaccination/antibody administration (day 2 and 4 after tumor implantation) and 
continued every 7 days therafter. LM CTLA4 IgG2a treatment schedule was the 
same as in Figure 3-1a. Outgrowth was followed until the first tumors reached 
>2000 mm^3.  Representative of 1 experiment, 5 mice per group.  
 
 






































































































Combination Listeria + Checkpoint blockade dramatically changes the tumor 






The production of cytokines by both immune cells and non- immune stromal cells 
shapes the tumor micro environment. Recently, the field has come to appreciate that 
multifunctional t cells, those that produce multiple different cytokines, represent the most 
effective subset of cells and are not only a good readout for vaccine efficacy, but a good 
prognosis for tumor clearance. Thus, probing to see if vaccination induces these cells is a 
major output for therapeutic vaccines. Similarly, analyzing the whole of the tumor 
microenvironment for cytokine presence allows an understanding of the 
microenvironment that cells experience while undergoing their functions. Many tumor 
types, including B16, 4T1, and Her2, have tolerizing tumor microenvironments 
characterized by the presence of TGF-b and IL-10. Through vaccination, we seek to skew 
this environment from one of immunosuppression to one of immune activation.  
Additionally, the presence and absolute number of infiltrating lymphocytes is 
crucial for immune clearance of tumors. B16F10 is a relatively uninfiltrated tumor at is 
basal state, and inducing strong infiltration of lymphocytes into the tumor 
microenvironment is key to initiating immune mediated killing.  Conversely, Tregulatory 
cells infiltrating in the tumor will prevent the effector function of CD8+ Tcells, and as 





Chapter Specific Material and Methods 
Cell Lines 
B16F10 and CT26 were acquired from ATCC (CRL-6475, and CRL-2639 
Respectively) and were cultured in Complete RPMI (10%FBS, 100u/ml penicillin, 
100ug/ml streptomycin, 250ng/ml amphotericin, 1mM sodium pyruvate, NEAA).  
Mice 
C57BL/6 mice (6-8 week old female) were purchased from Jackson Laboratories 
and BL6-CD45.1 mice (6-8 week old female) were purchased from Charles River. All 
mouse procedures were approved by the Johns Hopkins University Institutional Animal 
Care and Use Committee and were compliant with the Guide for the Care and Use of 
Laboratory Animals (8th ed. The National Academic Press. 2011). 
Antibodies 
Therapeutic antibodies aCTLA-4 IgG1 (9D9), aCTLA-4 IgG2a (9D9), aPD-1 
(4H2), anti-DT mIgG1 (1D12) and anti-DT mIgG2a (1D12) were acquired in collaboration 
with Alan Korman and Mark Selby at Bristol-Myers Squibb.  Dosing per injection was 200 
ug for all antibodies, administered IP in 200ul PBS. 
Immunohistochemistry antibodies included CD3 (SP7), ThermoScientific; CD4 
(1), SinoBiological; FoxP3(D608R), Cell Signaling.   
Flow cytometry staining antibodies included CD4-Pacific orange (RM4-5) 
Invitrogen; CD4-FITC (GK1.5), CD8-PerCP/Cy5.5 (53-6.7), CD44-Pacific Blue (IM7), 
CD11b-AlexaFluor700 (M1/70), CD11c-FITC (N418), F4/80-Pe/Cy7 (BM8), 
CD16.2(FcRIV)-PE (9E9), FoxP3-APC (FJK-16s), CD25-PerCp/Cy5.5 (PC61), CTLA4-
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PE (UC10-4B9), CD86-PE/Cy5 (GL-1), IFN-gamma-PE/Cy7 (XMG1.2),CD45-BV605 
(30-F11), IFNy-APC(XMG1.2), Gzb-Pacific Blue (GB11),  BioLegend; GranzymeB-PE 
(16G6), CD4-PerCP Cy5.5 (RM4-5), Viability Dye- APC-Cy7, CD8-FITC (53-6.7), 
CD44-AF700 (IM7), TNFa-PE (MP6-XT22), eBioscience; TNF-APC (MP6-XT22), BD 
Biosciences; IL-2-PE-CF594 (JES6-5H4), BD Horizon.  
LM/2a Tumor Outgrowth and Infiltration Studies 
5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. On day 5, mice were vaccinated via the tail vein with Listeria or given sham treatment. 
On days 5, 7, and 9, mice were given 200ug (in 200ul PBS) of blockade antibodies or PBS 
alone. On day 18 mice were sacrificed. Tumor volume was calculated by the following 
equation: (Length*Width^2)/2. Cell number of spleen and lymph node were counted on a 
hemocytometer while cell numbers of tumor infiltrate were acquired by flow cytometry. 
For Cytokine intracellular staining, animals sacrificed and tumors were harvested 10 days 
after implantation. Whole tumor suspension was incubated with PMA and Ionomycin for 
4.5 hours. Cells were fixed for 30 minutes in Fixation/Permeablilization buffer by BD 
Bioscience (Cat. No. 554714 and 554715) before proceeding to stain.  
Cytokine Array 
Blood serum was collected by cheek bleed on days 8 and 11, then by incision of 
the IVC on day 14. Blood sat to clot for 10 minutes then was centrifuged and serum was 
harvested. The Luminex Biorad Mouse Group 1 23-plex assay (#M60-009RDPD) was 
conducted following vendor guidelines. Serum samples were diluted 1:4. Standard curves 
were generated and within the normal ranges expected with the exception of a reduced 




Statistical significance for bar graphs was determined with a one-sided or two sided 
non-Paired students T test (*=P<.05, **=P<.001, ***=P<.0001). Statistical significance 










Lymphocyte and Systemic Cytokine levels are increased by vaccination + 
checkpoint blockade. 
We hypothesized that the enhanced tumor clearance due to combination therapy 
may be due to an enhanced effector T cell response. Thus, we sacrificed animals treated 
in the above strategy 10 days after tumor implantation, re-stimulated TIL ex vivo with 
PMA and Ionomicin, and analyzed the lymphocytes for their ability to produce effector 
cytokines. We found that after vaccination, Listeria and both aCTLA-4 antibodies 
enhance Granzyme B and Interferon Gamma production by TIL and reduce the number 
of cells that produce zero measurable cytokines. However, administration of aCTLA-4 
(D) enhanced cytokine production and multi-functionality of TIL to a greater degree than 
both LM or aCTLA-4 (ND) monotherapies. The combination LM+aCTLA-4 (D) led to 
the greatest cytokine production, although it was not significantly higher than aCTLA-4 
(D) alone (Figure 4-1a-b). To analyze the levels of systemic cytokines within mice, we 
performed blood cytokine analysis by acquiring blood serum from animals at 3,7, and 11 
days after vaccination. 3 days after vaccination, systemic cytokine levels are generally 
elevated in mice that have received LM and enhanced further with the addition of 
checkpoint antibodies (Figure 4-2). Interestingly, we noted an overall increase in all 
measured systemic cytokine levels in untreated animals as well as most measured 
systemic cytokine levels in treated animals over time. On day 7 and 11, differences 






Combination LM-M+aCTLA4-IgG2a therapy robustly depletes Tregs in the 
tumor and allows for Tumor infiltration. 
Because we observed increases in functionality of tumor immune infiltrate, we 
then analyzed the abundance of Treg and Teff lymphocytic infiltrate in the tumor 
microenvironment and periphery. We firstly examined the expression of CTLA-4 across 
cell types and confirmed that tumor infiltrating Treg highly express CTLA-4, even when 
compared to their peripheral counterparts (Figure 4-3a). We then analyzed mice treated 
as in Figure 3-1a for peripheral and Tumor infiltrating CD4+ FoxP3+ Treg. Not 
surprisingly, while Treg in the periphery stay relatively constant (data not shown) 
independent of treatment, Tumor infiltrating Treg percentages are highly reduced in LM 
treated, as well as aCTLA-4 (D) treated animals. When LM+aCTLA-4 (D) combination 
strategy is applied, Treg generally account for only 1-5% of CD4+ cells in the tumor as 
opposed to ~40% in untreated animals (Figure 4-3b-c). We next analyzed the number of 
Infiltrating lymphocytes in each of our treatments and show infiltration of lymphocyte 
very closely follows the depression of Treg percentages. LM increases infiltrate of both 
CD4+ and CD8+ cells as a monotherapy. However, aCTLA-4 (D) as a monotherapy or in 
combination with LM strongly induces infiltration of lymphocytes into the tumor 
environment (Figure 4b). Interestingly, almost all lymphocytes in the tumor are CD44+ 
in the untreated group, and this number generally does not increase with most treatments 
(data not shown). Because the CD4+ and CD8+ Tumor infiltrate increases concurrently 
with the decrease in Tregulatory cells, this treatment strategy allows for a high Teff:Treg 
ratio. Lastly, we stained for the presence of CD3 positive infiltrating cells across our 
34 
 
treatment groups using immunohistochemistry (IHC) on FFPE tumors (Figure 4-4a). 
While LM treatment alone shows a moderate increase in infiltrating CD3+ cells (red), 
aCTLA-4 (D) alone or in combination with LM vastly increases the lymphocytic 
infiltrate in the tumor. In fact, we observe foci of CD3+ cells in the middle of tumor areas 


















Figure 4-1: Lymphocyte and systemic cytokine levels are increased by 
vaccination + checkpoint blockade. (A) Mice were implanted with tumor and 
treated as in Figure 3-1.  On Day 18, TIL were harvested and restimulated with 
PMA+Ionomicin and cytokine expression was examined by FACS. (B) Graph of 
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Figure 4-2. LM vaccination increases peripheral cytokines: 8 days after 
treatment, animals were bled via the tail vein and serum was collected. Serum was 
Low                  High 
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diluted 1:4 and applied to a Luminex array and cytokines were measured.  Data is 


















































































Figure 4-3:  Tregulatory cells are effectively depleted with LM and aCTLA-4 (D) 
strategies. (All plots represent data collected on day 18 after treatment as in 
Figure 1a. (A) CTLA4 MFI on FoxP3+ cells across all treatment groups as 
measured by flow cytometry. All treatment groups were binned together and 
expression was examined based on location of cells. (B-C) Flow Cytometry plots 



















Figure 4-4: Effector cell infiltrate is greatly increased with LM+aCTLA-4 
vaccination. (A) IHC of FFPE stained tumor sections, CD3+ cells in red. Bar 
graphs and FACS plots are representative of multiple similar experiments with 5 
mice per group. IHC was performed in two separate experiments on a total of 5 or 
more mice. (B) Absolute numbers of tumor infiltrating CD4 and CD8 cells were 
analyzed by flow cytometry and divided by wet weights of tumors to determine 















Antibody dependent cellular cytotoxicity (ADCC) is the phenomenon by which 
antibodies aid in the killing of cells. Antibodies are comprised of several different 
structural and functional components. For the sake of this introduction, we will focus on 
the Fab portion and the Fc portion. Endogenous or artificially introduced antibodies bind 
to their target cells at the variable region, or Fab, of the antibody, which is exquisitely 
specific for the target. The other portion of the antibody structure is the constant region, 
or Fc. The Fc portion of the antibody is the ligand for Fc-Receptors, which are Fc-
binding proteins located on phagocytic or cytotoxic cells throughout the body. While 
multiple cell types can express Fc receptors, natural killer (NK) cells and macrophages 
express the widest variety in the highest abundance, and thus are thought to be the main 
cellular mediators of ADCC.   
There are several classes of Fc Receptors, each with specific functions. Generally 
grouped into activating Fc receptors, which stimulate the cell bearing them and induce 
apoptosis of the antibody-bound target, and inhibitory Fc receptors, which do not aid in 
ADCC and are thought to prevent phagocytosis or killing of the target.  Recently, isotypic 
differences in checkpoint blockade antibodies have been implicated in the efficiency of 
ADCC based depletion100. In mice, isotype IgG2a binds Fc receptors with higher affinity, 
and thus corresponds with highly effective depletion while IgG1 is less effective at 





Chapter Specific Materials and Methods 
Cell Lines 
B16F10 and CT26 were acquired from ATCC (CRL-6475, and CRL-2639 
Respectively) and were cultured in Complete RPMI (10%FBS, 100u/ml penicillin, 
100ug/ml streptomycin, 250ng/ml amphotericin, 1mM sodium pyruvate, NEAA).  
Mice 
C57BL/6 mice (6-8 week old female) were purchased from Jackson Laboratories 
and BL6-CD45.1 mice (6-8 week old female) were purchased from Charles River.FoxP3 
DTR mice were a gift from Dr. Drew Pardoll and FcgR-/-  (B6.129P2-Fcer1gtm1RavN12) 
breeder mice were purchased from Taconic and bred in Johns Hopkins Facilities. All 
mouse procedures were approved by the Johns Hopkins University Institutional Animal 
Care and Use Committee and were compliant with the Guide for the Care and Use of 
Laboratory Animals (8th ed. The National Academic Press. 2011). 
Antibodies 
Therapeutic antibodies aCTLA-4 IgG1 (9D9), aCTLA-4 IgG2a (9D9), aPD-1 
(4H2), anti-DT mIgG1 (1D12) and anti-DT mIgG2a (1D12) were acquired in collaboration 
with Alan Korman and Mark Selby at Bristol-Myers Squibb.  Dosing per injection was 200 
ug for all antibodies, administered IP in 200ul PBS.  
Flow cytometry staining antibodies included CD4-Pacific orange (RM4-5) 
Invitrogen; CD4-FITC (GK1.5), CD8-PerCP/Cy5.5 (53-6.7), CD44-Pacific Blue (IM7), 
CD11b-AlexaFluor700 (M1/70), CD11c-FITC (N418), F4/80-Pe/Cy7 (BM8), 
CD16.2(FcRIV)-PE (9E9), FoxP3-APC (FJK-16s), CD25-PerCp/Cy5.5 (PC61), CTLA4-
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PE (UC10-4B9), CD86-PE/Cy5 (GL-1), IFN-gamma-PE/Cy7 (XMG1.2),CD45-BV605 
(30-F11), IFNy-APC(XMG1.2), Gzb-Pacific Blue (GB11),  BioLegend; GranzymeB-PE 
(16G6), CD4-PerCP Cy5.5 (RM4-5), Viability Dye- APC-Cy7, CD8-FITC (53-6.7), 
CD44-AF700 (IM7), TNFa-PE (MP6-XT22), eBioscience; TNF-APC (MP6-XT22), BD 
Biosciences; IL-2-PE-CF594 (JES6-5H4), BD Horizon.  
LM/2a Tumor Outgrowth and Infiltration Studies 
5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. On day 5, mice were vaccinated via the tail vein with Listeria or given sham treatment. 
On days 5, 7, and 9, mice were given 200ug (in 200ul PBS) of blockade antibodies or PBS 
alone. On day 18 mice were sacrificed. Tumor volume was calculated by the following 
equation: (Length*Width^2)/2. Cell number of spleen and lymph node were counted on a 
hemocytometer while cell numbers of tumor infiltrate were acquired by flow cytometry. 
For Cytokine intracellular staining, animals sacrificed and tumors were harvested 10 days 
after implantation. Whole tumor suspension was incubated with PMA and Ionomycin for 
4.5 hours. Cells were fixed for 30 minutes in Fixation/Permeablilization buffer by BD 
Bioscience (Cat. No. 554714 and 554715) before proceeding to stain.  
Statistics: 
Staticstical significance for bar graphs was determined with a one-sided or two 
sided non-Paired students T test (*=P<.05, **=P<.001, ***=P<.0001). Statistical 





LM-M/CTLA4 Combination therapy are FCR dependent 
Previous research has shown that IgG2a dependent ADCC occurs through Fc 
gamma receptor 4 (FcgRIV). We hypothesized that LM may synergize with aCTLA4 and 
enhance ADCC through activation of macrophages to express higher levels of surface 
FcgRIV. To assess this we treated WT mice as in Figure 1a and measured FcgRIV 
expression by flow cytometry. Both LM (not significant) and aCTLA-4 (D) 
administration increased the number of FcgRIV + macrophages (Figure 5-1b) and the 
MFI of FcgRIV(Figure 5-1a).  We next examined the outgrowth and lymphocytic 
compartment of Fc common gamma chain knockout mice (FcgR-/-). Unsurprisingly, 
FcgR-/- mice are unable to control tumor to the same degree as WT mice when 
administered aCTLA-4 (D)(Figure 5-2a). Tregulatory cells are still reduced with LM 
treatment in these animals, but not with aCTLA-4 (D) treatment, showing that Fc 
receptors are necessary for aCTLA-4 (D) dependent ADCC of Treg (Figure 5-2b). 
Concurrently, while LM+CTLA4 (D) increases CD4+ and CD8+ TIL in WT animals, 
FcgR-/- animals show a marked reduction in the ability to induce an immune infiltrate 
when treated with aCTLA-4 (D) alone (Figure 5-2c). Treatment LM increases these 
numbers, but cannot fully rescue infiltration in a WT vaccinated animal. All these data 
suggest that aCTLA-4 (D) reduces tumor Treg through Fc Gamma receptors, and that our 
vaccination strategy not only acts through the presence of these receptors, but can also 












Figure 5-1: CTLA4 (D) therapeutic effect is ablated in FcgR-/- mice. Mice were 
treated according to Figure 3-1.  (A) 10 Days after tumor implantation, tumors 
from WT animals were harvested and analyzed via flow cytometry for FcgRIV 
expression on CD11b+F4/80+ cells. Graph of FcgRIV MFI and representative 
histograms of FcgRIV MFI in CD11b+F4/80+ Cells.  (B) Macrophage frequency 
was measured by calculating the number of CD11b+F4/80+ Cells per 100,000 
events.  Data is representative of at least 2 similar experiments with 5 mice per 































































































































Figure 5-2. Outgrowth and Treg Depletion by CTLA-4 are Fc receptor 
dependent. (A)WT or FcgR-/- mice, treated as in Figure 3-1, were measured and 
followed for outgrowth.  (B,C) 18 Days after tumor implantation, WT or FCGR-/- 
TIL was analyzed by Flow cytometry. Cell numbers and frequencies were 
calculated as in Figure 3. Data is representative of at least 2 similar experiments 







































































































































































































































Therapeutic Intratumoral Injection of CDN leads to acute rejection of B16F10 







Recent data suggests that the cGAS-STING axis not only determines outcomes to 
bacterial and viral insult, but also to self-DNA in cancer models96,102-108. STING deficient 
mice lack the ability to reject highly immunogenic tumors, and have accelerated tumor 
outgrowth in less immunogenic tumor models. Interestingly, these studies also show that 
tumor DNA can be found in dendritic cells, and that these cells are necessary to initiate 
an adaptive immune response107. Sparked by these discoveries, studies have begun to 
utilize CDN as an immunotherapeutic agent. Administration of small doses of CDN 
intravenously (IV) can aid in initiating an adaptive immune response, however, IV dosing 
of this agent seems to be delicate in that high concentrations of CDN can produce sub 
optimal or even immune suppressive conditions95. If administered intratumorally (IT), 
some tumor cell lines are directly effected by sting activation and undergo apoptosis. 
However, this direct killing of tumor cells seems to be a rare event, IT CDN 
administration more often induces tumor regression by inducing cellular infiltrate and  
inflammatory cytokine environment102.  
While the effects of sting signaling on adaptive immune cells have begun to 
become elucidated, relatively little data has been shown on the effects of CDN on the 
stromal cell compartment. Endothelial cells have been shown to produce interferon-b 
after CDN administration109, but no study has shown the importance of TNFa production 
on the tumor microenvironment, and no study has definitively shown that production of 
innate cytokines is necessary for acute tumor necrosis and immune infiltrate modulation. 
Additionally, we are the only group to use bone marrow chimeras to show the 
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dependence of tumor necrosis on STING sensing within stromal cells and that stromal 




Chapter Specific Materials and Methods 
Cell Lines 
B16F10 and CT26 were acquired from ATCC (CRL-6475, and CRL-2639 
Respectively) and were cultured in Complete RPMI (10%FBS, 100u/ml penicillin, 
100ug/ml streptomycin, 250ng/ml amphotericin, 1mM sodium pyruvate, NEAA).  
Mice 
C57BL/6 mice (6-8 week old female) were purchased from Jackson Laboratories 
and BL6-CD45.1 mice (6-8 week old female) were purchased from Charles River.FoxP3 
DTR mice were a gift from Dr. Drew Pardoll and FcgR-/-  (B6.129P2-Fcer1gtm1RavN12) 
breeder mice were purchased from Taconic and bred in Johns Hopkins Facilities. cGAS-/- 
animals were a gift from Skip Virgin. STING-/- animals are the Golden Ticket strain, and 
were a gift from Young Kim. Rag2-/- animals were a gift from Jonathan Powell. IFNar-/- 
(B6.129S2-Ifnar1tm1Agt/Mmjax), TNFa-/- ( B6.129S-Tnftm1Gkl/J), and IL-6-/- 
(B6;129S2-Il6tm1Kopf/J) breeder pairs were purchased from Jackson laboratories and 
bred in Johns Hopkins Facilities. All mouse procedures were approved by the Johns 
Hopkins University Institutional Animal Care and Use Committee and were compliant with 
the Guide for the Care and Use of Laboratory Animals (8th ed. The National Academic 
Press. 2011). 
Antibodies 
For CDN studies antibodies used included CD11b-AF700 (M1/70), CD44-Pacific 
Blue (IM7), CD11c-FITC (N418), CD86-PE (GL-1), CD19 PerCP-Cy5.5 (6D5), Ly6C-
BV605(HK1.4), CD45.2- APC (104), IA/IE- PerCP-Cy5.5 (M5/114.15.2), Ly6G- BV421 
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(1A8), CD16/32-BV510 (93), F4/80-PE-Cy7 (BM8), CD206-BV711 (C068C2), Ly6c- 
PerCP- Cy5.5 (HK1.4), and CD4- BV605 (GK1.5), Biolegend; NOS2-APC (CXNFT), 
NK1.1-PE (PK136), and CD8-PE-Cy7 (53-6.7), EBiosicence; CD4-Pacific Orange (RM4-
5), Life Technologies; CD45.1-FITC (A20) BD Pharmingen. 
CDN Tumor Outgrowth and Infiltration studies 
5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. Tumors were monitored until the group average was ~80mm^3 and then treated with 
100ug injections of CDN in 40ul PBS or PBS alone every other day for a total of three 
treatments. For chimera studies, a surplus of mice were implanted tumor, then when tumors 
were palpable, animals were selected and groups normalized to ~80mm^3. Tumor 
outgrowth volume was measured by the equation V=1/2(width^2*length). 24 hours after 
treatment, some mice were sacrificed for tumor infiltrate studies by flow cytometry or for 
tumor lysate. Tumor lysate was made by resecting tumors and dissociating in Cell Lytic M 
(Sigma Cat no. C2978) with Protease Inhibitor Cocktail (Sigma S8820).   
Elisa: 
Elisas were purchased as kits as follows:  Mouse IL-1b/IL-1f2 (Catalog No. 
MLB00c), Mouse GM-CSF (Catalog No. MGM00), Mouse IL-6 (Catalog No. M6000B), 
Mouse TNF-a (Catalog No MTA00B) R&D; VeriKine Mouse IFNb Elisa (Catalog No 
42400-2) PBL Assay Science; Mouse Inflammatory Cytokines Multi-anylite ELISArray 






Therapeutic Intratumoral Injection of CDN leads to acute rejection of B16F10. 
Because CDN’s have been shown to be potent adjuvants and because direct 
injection of adjuvant is now being used in clinical trials, we sought to understand the 
effect of adjuvant injection on the tumor microenvironment. To do this, we implanted 
B16F10 tumors in the flank of mice and treated mice with tumors of volume 80-100 
cm^3 with 3x 40 ul injections of 100ug RR-di adenosine CDN (Figure 6-1a).  Within 48 
hours of the first injection, redness and necrosis forms around the injection site. Within 5 
days of injection, an eschar has formed and tumor is no longer palpable. At 8 days after 
first treatment, untreated animals have large tumors and may need to be sacrificed, but 
treated animals generally have only a eschars (Figure 6-1c,d). Occasionally injection and 
necrosis of the tumor is incomplete and healthy growing tumor can be seen, even around 
the site of injection (Figure 6-1e). Several weeks after injection, mice that have 
completely cleared tumor have healed but show reaction site vitiligo indicating the 
presence of an ongoing, melanin specific adaptive immune response (Figure 6-1f).  
 IT CDN injection causes a distinct cytokine and cellular profile in the tumor.  
To gain an understanding into the cause of necrosis within the tumor, we 
performed extensive analysis of the systemic and tumor infiltrating cytokines and 
immune cells before and after intratumoral CDN administration. 24 hours after the initial 
injection, we sacrificed animals and analyzed spleen, tumor draining lymph node and 
tumor for cellular infiltrate via flow cytometry. Due to the acute nature of tumor 
rejection, we did not expect that adaptive immune infiltrate and killing would be 
enhanced in the tumor, and in fact injection of high dose CDN caused a decrease in T and 
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B cell numbers acutely (figure 6-2). This decrease in the lymphocytic compartment may 
be due to toxicity of high dose CDN to lymphocytic cells (unpublished data). On the 
contrary, CDN administration increased the number of tumor infiltrating CD11b+F4/80+ 
macrophages as well as CD11b+F4/80- neutrophils (these cells are further characterized 
by the high expression of Ly6g and low expression of Ly6c). NK cell numbers were not 
effected in the tumor. Interestingly, the tumor draining lymph node experiences a similar 
decrease in T cell percentages, though not B cell percentages, along with a large increase 
of high FSC and SSC cells that are a large percentage macrophages and other APC 
(Figure 6-3). 
We next examined intratumoral cytokine levels by resecting tumors and creating 
whole tumor lysate. After tumors were homogenized and lysed, we performed a 
multiKine ELISA. 24 hours after the initial injection of CDN, we observed highly 
significant increases in the amount of IL-6, TNFa, IFNb, IL-1, and GMCSF within the 






















Figure 6-1: IT CDN treatment leads to tumor regression in B16F10 tumor 
bearing animals.  (A) Animal treatment scheme. 5x10^5 B16F10 cells were 
implanted between the skin and peritoneal cavity on day 0. Tumors were 
monitored until the group average was ~80mm^3 and then treated with 100ug 
injections of CDN in 40ul PBS or PBS alone every other day for a total of three 
treatments. (B) Outgrowth of animals treated as in (A). (C-D) Photos of tumors 8 
Days after CDN (C) or PBS (D) show necrosis at the tumor site. (E) Close-up of 
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Figure 6-2: IT CDN changes tumor immune infiltrate. (A) 24 hours after IT CDN 
























































































Figure 6-3: IT CDN changes tumor draining lymph node immune infiltrate. (A) 
24 hours after IT CDN administration, mice are sacked and the tumor draining 
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Figure 6-4: Cytokine concentrations in tumor microenvironment increase after IT 
CDN. 24 hours after IT CDN administration, tumor lysates were prepared as 







































































































TNFa production is necessary for IT CDN related necrosis and is produced by both 








Previously, we have shown that the IT injection of CDN results in the increase of 
several cytokines and cell types within the TME. In looking more closely at the cytokine 
profile and cellular resulting from acute necrosis that we observe after, we hypothesized 
that a few key factors could be responsible for this necrosis. Most obviously, tumor 
necrosis factor has a well established function of inducing necrosis among various cell 
types expressing the receptor. 
  Tumor Necrosis Factor alpha (TNFa) is an inflammatory cytokine made of 3-
17kD subunits in a trimeric form.110 It generally though of as a pro-inflammatory 
cytokine, it triggers dilation of blood vessels and leakage of fluid and cells into 
surrounding tissues. In systemic infection, massive release of TNFa can lead to septic 
shock.111 In high doses, TNFa can also cause necrosis of tissues expressing the proper 
receptor. TNFa binds to one of two receptors, named TNFR-1 and TNFR-2.  TNFR-1 is 
expressed by a wide variety of cell types, whereas TNFR-2 is generally only expressed 
on immune cells.  Ligation of both receptors can lead to the transcription of NFkB and 
pro-survival gene transcription through the binding of the TRADD scaffold protein. 
TNFR-1, however, is unique in it’s ability to bind a Fas associated death domain (FADD) 
that can lead to cleavage and activation of pro-caspase 8 and pro-caspase 3. The 
activation of the effector caspase 3 in turn initiates apoptosis of the cell expressing 
TNFR-1.112 Thus, TNFa plays an important roll in activating immune cells, but can have 
apoptic effects in non-immune cells.  
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TNFa is mainly produced by hematopoietic cells of the immune system.102 
Macrophages in particular can produce large amounts of TNFa in response to ligation by 
TLR agonists. However it is now well characterized that TNFa is also produced by non-
immune stromal cells such as endothelial cells, fibroblasts, and tumor cells.80,113,114  
Because a growing body of literature suggests the importance of cellular and 
cytokine infiltrate in tumor clearance, we sought to systematically eliminate possible 











B16F10 and CT26 were acquired from ATCC (CRL-6475, and CRL-2639 
Respectively) and were cultured in Complete RPMI (10%FBS, 100u/ml penicillin, 
100ug/ml streptomycin, 250ng/ml amphotericin, 1mM sodium pyruvate, NEAA).  
Mice 
C57BL/6 mice (6-8 week old female) were purchased from Jackson Laboratories 
and BL6-CD45.1 mice (6-8 week old female) were purchased from Charles River.FoxP3 
DTR mice were a gift from Dr. Drew Pardoll and FcgR-/-  (B6.129P2-Fcer1gtm1RavN12) 
breeder mice were purchased from Taconic and bred in Johns Hopkins Facilities. cGAS-/- 
animals were a gift from Skip Virgin. STING-/- animals are the Golden Ticket strain, and 
were a gift from Young Kim. Rag2-/- animals were a gift from Jonathan Powell. IFNar-/- 
(B6.129S2-Ifnar1tm1Agt/Mmjax), TNFa-/- ( B6.129S-Tnftm1Gkl/J), and IL-6-/- 
(B6;129S2-Il6tm1Kopf/J) breeder pairs were purchased from Jackson laboratories and 
bred in Johns Hopkins Facilities. All mouse procedures were approved by the Johns 
Hopkins University Institutional Animal Care and Use Committee and were compliant with 
the Guide for the Care and Use of Laboratory Animals (8th ed. The National Academic 
Press. 2011). 
Chimeric animals were made by irradiating 6-12 week old animals with 2 doses of 
6 gy separated by 3 hours. 3 hours after the second dose of irradiation, mice were 
reconstituted with 5-10 million cells of unirradiated donor bone marrow via tail vein 
injection and left to rest for at least 6 weeks. All chimeric animals were put on uniprim 
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feed at least 1 week before irradiation and removed from uniprim feed at least 1 week 
before tumor challenge.  
 
 
CDN Tumor Outgrowth and Infiltration studies 
5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. Tumors were monitored until the group average was ~80mm^3 and then treated with 
100ug injections of CDN in 40ul PBS or PBS alone every other day for a total of three 
treatments. For chimera studies, a surplus of mice were implanted tumor, then when tumors 
were palpable, animals were selected and groups normalized to ~80mm^3. Tumor 
outgrowth volume was measured by the equation V=1/2(width^2*length). 24 hours after 
treatment, some mice were sacrificed for tumor infiltrate studies by flow cytometry or for 
tumor lysate. Tumor lysate was made by resecting tumors and dissociating in Cell Lytic M 
(Sigma Cat no. C2978) with Protease Inhibitor Cocktail (Sigma S8820).   
Elisa: 
Elisas were purchased as kits as follows:  Mouse IL-1b/IL-1f2 (Catalog No. 
MLB00c), Mouse GM-CSF (Catalog No. MGM00), Mouse IL-6 (Catalog No. M6000B), 
Mouse TNF-a (Catalog No MTA00B) R&D; VeriKine Mouse IFNb Elisa (Catalog No 
42400-2) PBL Assay Science; Mouse Inflammatory Cytokines Multi-anylite ELISArray 




Staticstical significance for bar graphs was determined with a one-sided or two 
sided non-Paired students T test (*=P<.05, **=P<.001, ***=P<.0001). Statistical 






TNFa Is required for Injection Site Necrosis  
Because we observed distinct cellular and cytokine signatures after CDN 
injection, we hypothesized that these elements may be responsible for tumor site necrosis. 
To elucidate the minimal requirements for CDN-mediated injection site necrosis, we 
performed the same treatment scheme as in Figure 6-1a in a series of knockout mice.  
Unsurprisingly, while WT mice control tumors acutely, STING-/- animals lack the ability 
to sense CDN and clear tumor. cGAS-/- animals have no deficit in tumor clearance, 
showing that the upstream sensor of the sting pathway has no gross effect on the 
downstream signaling (Figure 7-1). RAG2-/-, IFNar-/-, and IL-6-/- animals all showed 
the same tumor site necrosis as WT animals. Interestingly, the type 1 Interferon receptor 
is a necessary mediator of many immune pathways, and thus tumors in these grow much 
faster (Figure 7-2a). This increased rate subverts some of the effect of CDN and CDN 
therapy is not curative in these animals in a B16 tumor system (Figure 7-2b). However, in 
a non-tumor bearing animal, injection site necrosis occurs in the same manner as a WT 
animal, showing that IFNar is not an important mediator of the acute response to CDN. 
Interestingly, the only animals to show absolutely no injection site necrosis after CDN 
injection were TNFa-/- animals.  
Bone Marrow produced TNFa is predominates the tumor microenvironment. 
We observed that TNFa is a necessary effector of CDN-mediated tumor site 
necrosis, and hypothesized that because bone marrow derived cells are largely 
responsible for the production of CDN, TNFa producing bone marrow cells would be 
required for injection site necrosis. To answer this, we developed a series of bone marrow 
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chimeras by irradiating WT or TNFa-/- hosts and reconstituting them with either WT or 
TNFa bone marrow. As hypothesized, animals with WT bone marrow have a more 
dramatic response to IT CDN therapy (Figure 7-3a). These animals have higher levels of 
intratumoral TNFa compared to their TNFa-/- bone marrow counterparts, clear tumor 
more efficiently than their counterparts, and have more injection site necrosis than their 
counterparts (Figure 7-3a-b). It should, however, be noted, that TNFa-/-  WT bone 
marrow chimeric animals do form some necrosis and have a reduction in tumor burden 
when compared to TNFa-/-TNFa-/-  chimeric controls. Based on these observations, 
we conclude that while both stromal and bone marrow derived TNFa contributes to 


























Figure 7-1: TNFa is required for injection site necrosis after IT CDN therapy. Tumors 
were implanted as above and outgrowth in knockout animals was assessed for volume 





































































































































































































































Figure 7-2: Tumor outgrowth is enhanced in IFNar, STING, cGAS, and RAG-/- 
animals.  (A-B) Tumor outgrowth on day 12 of untreated (A) and IT CDN treated 

































































































































































































Figure 7-3:  TNFa produced by both bone marrow and stroma aids in the 
clearance of B16F10.  (A) Outgrowth plots and representative pictures of 
TNF/WT chimeric animals. (B) Elisa of tumor lysate taken 24 hours after IT CDN 
















































































































































With the exception of microglial cells, tissue resident macrophages, and few 
others, cells of the immune system are generally all derived from hematopoietic stem 
cells of bone marrow. The common lymphoid progenitor gives rise to all B cells, T cells, 
and NK cells, whereas the common myeloid progenitor gives rise to Basophils, 
neutrophils, and monocytes that spawn macrophages and dendritic cells. These cell 
subsets comprise the specialized cells of the immune system, and are exquisite at 
performing their duties within the immune system. However these are not, by a long 
stretch, the only cells that take part in immune reactions.  Many cell types in the body 
have the capability to initiate an immune response through activation of any of several 
mechanisms, as discussed in the section “stromal cells” above. TLR agonists are not only 
found on immune cells, but on in the liver, on brain microglia, on epithelial cells in the 
gut, lung, and even musculature78,81. Viral sensors like RIG-I and MDA5, which potently 
initiate production of type 1 interferons, can be found in many cell types including 
endothelial, epithelial, and fibroblast cells79-81. Lastly, DNA sensors like cGAS as well as 
STING can be found in the cytosol and ER of multiple cell types115.  
The prolific expression of these sensors means that, while far too often 
immunologist only consider the effects of adjuvants on immune cells, we should strongly 
consider the effect of these compounds on non-immune endothelial, epithelial, and other 
stromal cell subsets. Previous research has suggested that Type 1 interferon can be 
produced by CD31+ endothelial cells in response to IT CDN109. While we have 
concluded that TNFa is vastly more important for acute necrosis in our system, we show 
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here, with a series of bone marrow chimeras, that sensing of CDN by stromal cells may 









B16F10 and CT26 were acquired from ATCC (CRL-6475, and CRL-2639 
Respectively) and were cultured in Complete RPMI (10%FBS, 100u/ml penicillin, 
100ug/ml streptomycin, 250ng/ml amphotericin, 1mM sodium pyruvate, NEAA).  
Mice 
C57BL/6 mice (6-8 week old female) were purchased from Jackson Laboratories 
and BL6-CD45.1 mice (6-8 week old female) were purchased from Charles River.FoxP3 
DTR mice were a gift from Dr. Drew Pardoll and FcgR-/-  (B6.129P2-Fcer1gtm1RavN12) 
breeder mice were purchased from Taconic and bred in Johns Hopkins Facilities. cGAS-/- 
animals were a gift from Skip Virgin. STING-/- animals are the Golden Ticket strain, and 
were a gift from Young Kim. Rag2-/- animals were a gift from Jonathan Powell. IFNar-/- 
(B6.129S2-Ifnar1tm1Agt/Mmjax), TNFa-/- ( B6.129S-Tnftm1Gkl/J), and IL-6-/- 
(B6;129S2-Il6tm1Kopf/J) breeder pairs were purchased from Jackson laboratories and 
bred in Johns Hopkins Facilities. All mouse procedures were approved by the Johns 
Hopkins University Institutional Animal Care and Use Committee and were compliant with 
the Guide for the Care and Use of Laboratory Animals (8th ed. The National Academic 
Press. 2011). 
Chimeric animals were made by irradiating 6-12 week old animals with 2 doses of 
6gy separated by 3 hours. 3 hours after the second dose of irradiation, mice were 
reconstituted with 5-10 million cells of unirradiated donor bone marrow via tail vein 
injection and left to rest for at least 6 weeks. All chimeric animals were put on uniprim 
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feed at least 1 week before irradiation and removed from uniprim feed at least 1 week 
before tumor challenge.  
 
Antibodies 
For CDN studies antibodies used included CD11b-AF700 (M1/70), CD44-Pacific 
Blue (IM7), CD11c-FITC (N418), CD86-PE (GL-1), CD19 PerCP-Cy5.5 (6D5), Ly6C-
BV605(HK1.4), CD45.2- APC (104), IA/IE- PerCP-Cy5.5 (M5/114.15.2), Ly6G- BV421 
(1A8), CD16/32-BV510 (93), F4/80-PE-Cy7 (BM8), CD206-BV711 (C068C2), Ly6c- 
PerCP- Cy5.5 (HK1.4), and CD4- BV605 (GK1.5), Biolegend; NOS2-APC (CXNFT), 
NK1.1-PE (PK136), and CD8-PE-Cy7 (53-6.7), EBiosicence; CD4-Pacific Orange (RM4-
5), Life Technologies; CD45.1-FITC (A20) BD Pharmingen. 
CDN Tumor Outgrowth and Infiltration studies 
5x10^5 B16F10 cells were implanted between the skin and peritoneal cavity on day 
0. Tumors were monitored until the group average was ~80mm^3 and then treated with 
100ug injections of CDN in 40ul PBS or PBS alone every other day for a total of three 
treatments. For chimera studies, a surplus of mice were implanted tumor, then when tumors 
were palpable, animals were selected and groups normalized to ~80mm^3. Tumor 
outgrowth volume was measured by the equation V=1/2(width^2*length). 24 hours after 
treatment, some mice were sacrificed for tumor infiltrate studies by flow cytometry or for 
tumor lysate. Tumor lysate was made by resecting tumors and dissociating in Cell Lytic M 




Elisas were purchased as kits as follows:  Mouse IL-1b/IL-1f2 (Catalog No. 
MLB00c), Mouse GM-CSF (Catalog No. MGM00), Mouse IL-6 (Catalog No. M6000B), 
Mouse TNF-a (Catalog No MTA00B) R&D; VeriKine Mouse IFNb Elisa (Catalog No 
42400-2) PBL Assay Science; Mouse Inflammatory Cytokines Multi-anylite ELISArray 
Kit (MEM004a), Quiagen.   
Statistics: 
Statistical significance for bar graphs was determined with a one-sided or two sided 
non-Paired students T test (*=P<.05, **=P<.001, ***=P<.0001). Statistical significance 
















Stromal STING sensing is required for injection site necrosis.  
Because TNFa production by both bone marrow and stromal cells appeared to 
have an effect in the previous chimeric animals, we sought to understand the relative 
contributions of CDN sensing and STING signaling in bone marrow and stromal cells. 
Again, we made a series of bone marrow chimeras by irradiating WT or STING-/- hosts 
and reconstituting them with either WT or STING-/- bone marrow. After IT CDN 
therapy, only animals with STING competent (WT) bone marrow (GTWT, WTWT) 
became necrotic at the IT CDN injection site while chimeras devoid of stromal STING 
(WTGT, GTGT) had no such necrosis (Figure 8-1a). Similarly, only WT host 
animals have detectable TNFa, IFNb, IL-6, and GM-CSF in tumor lysate when measured 
by ELISA (Figure 8-1b). Interestingly, there is an effect of tumor regression in both sets 
of chimeric animals to a close degree, suggesting that while WTGT animals have no 
observable innate necrosis or cytokine response, there may be other mechanisms, like an 
ongoing adaptive response, that control the tumor to some degree.  
To address the possibility of adaptive immune activation in all sets of chimeric 
animals, we analyzed the tumor draining lymph node(TDLN) infiltrate after CDN 
administration. All chimeras except GTGT experienced a significant infiltration of 
FSChi-SSChi cells into the TDLN (Figure 8-3). A large proportion of these cells were 
CD11b+CD11c+ dendritic cells, and in all chimeras except GTGT these dendritic cells 
upregulated the activation co-stimulatory molecule CD86 after CDN administration. This 





















Figure 8-1: Tumor necrosis only occurs in mice with STING competent stromal 
cells.  (A) Tumor outgrowth plots and pictures of chimeric animals treated with 
PBS or CDN. (B) ELISA of tumor lysate. 24 hours after IT CDN tumors were 


























































Figure 8-2: APC become activated via direct and indirect mechanisms after IT 
CDN. 24 hours after IT CDN administration, TDLN from CDN treated animals 
were harvested and analyzed by flow cytometry. APC were defined as high 
FSC/SSChi CD11c+CD11b+ cells. This population was then analyzed for CD86 



























Conclusion and Discussion  
 
The tumor microenvironment presents many barriers and challenges to the 
immune system.  However, these can be overcome through the use of agents to stimulate 
and shape the immune response as well as the tumor microenvironment in such a way 
that it becomes unaffected by these barriers.  In the above work, we have used the current 
and growing wealth of knowledge about the immune system and about the tumor 
environment to design and apply therapies that have proven potent in causing the 
regression of aggressive lethal tumors. However, not only have we designed therapies, 
but we have used them to gain a more full understanding of the immune system as it 
pertains to cancer. We have elucidated previously undiscovered mechanisms pertaining 
to the development of T regulatory cells as well as the contribution of the tumor stroma to 
initiating an anti-tumor immune response. In the future, we aim to continue these studies 
and understand further details of the immune reaction to cancer.  
Listeria+ Checkpoint Blockade Conclusions 
Administration of immunetherapeutic agents has shown resounding success lately 
in clinical trials as well as pre-clinical models. However, along with the successes, clear 
limitations of these approaches have become apparent. Absence of tumor infiltrating 
lymphocytes in tumors corresponds with poor responses in patients, so increasing the 
tumor infiltrate and creating de- novo tumor responses is a crucial step to overcoming 
those hurdles. We report that vaccination with LM-MEL, an engineered listeria 
bacterium, reduces tumor burden, increases the number and percentage of multifunctional 
CD8+ Tumor infiltrating lymphocytes and reduces the percent of CD4+ lymphocytes that 
are FoxP3+ from ~40% to ~30%. The addition of aCTLA-4 (D) to this vaccine increases 
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tumor lymphocytic infiltrate over 10-fold and dramatically enhances tumor responses 
through further depletion of Tregulatory cells from ~30% to ~1%.  This change in the 
cellular TIL compartment corresponds with a survival time of ~20 days when untreated 
to >40 days when treated.  
 
The field of antibody engineering is becoming exquisitely attentive to Fc receptor 
binding. Antibodies that react with Tcells, such as PD-1, can be engineered to have 
absolutely no interaction with Fc receptors, while those that react with immunosupessive 
compartments like Treg can be engineered to have maximal depletion efficiency. 
Unmentioned in these studies is manipulation of the other key element, the Fc receptor. 
Vaccines that can make depletion more efficient through upregulation of Fc receptors 
offer a double threat: activation of Tcells and enhancement of ADCC through 
monoclonal antibodies. To our knowledge, this is the first study that observes an increase 
in Fc expression as a result of vaccination. Listeria vaccination increases MFI of FcRIV 
by ~40%, and IgG2a increases this MFI another 2-4 fold. Our system is unfortunately not 
designed to determine if this upregulation of Fc receptor expression is functionally 
relevant, because LM, as we have shown, reduces Treg independently of Fc receptors and 
this confounds any conclusions we could draw.  
It has been shown that checkpoint blockade reduces the fraction of Treg as a 
percent of total tumor infiltrate and that the resulting Teff:Treg ratio is an important 
factor when predicting tumor clearance32,52. While data concur completely in this regard 
the mechanism behind this observation is not fully addressed. It seems that while 
aCTLA-4 administration reduces the percent of FoxP3+ cells as a fraction of TIL, that 
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effect is mostly due to the induction of CD4+FoxP3- infiltrate, not due to the obliteration 
of the Treg compartment. We in fact observe the opposite, a moderate increase in Treg in 
the tumor.  aCTLA-4 has been shown to reduce surface activation markers and the 
suppressive capacity of Treg in in vitro suppression assays30,116, but because we observe 
that tumor infiltration due to aCTLA-4 is isotype (IgG2a induces infiltrate while IgG1 
does not) and Fc receptor dependent rather than Fab dependent, it seems unlikely that 
Treg dysfunction explains all of this phenotype. Similarly, because we observe that 
aCTLA-4 increases numbers of infiltrating macrophages and expression of Fc receptors 
on those macrophages, we hypothesize that there is another mechanism yet to be 
explored.  
There are a few unexpected and unexplained results in our data. CD8 depletion 
does not lead to a complete abolition of tumor burden reduction. This is likely due to 
innate components of the immune system that we have left unexamined. Repolarization 
of TAM that might otherwise directly enhance tumor growth or activation of NK cells to 
kill tumor both may explain this vaccination effect. Additionally, aCTLA4 IgG1, 
supposedly “non-depleting” also leads to mild Treg depletion and increase of 
multifunctional CD8+ t cells. It should be noted that this antibody, while not optimized 
for depletion, still has the ability to bind Fc receptors, but with lower affinity. Lastly, the 
addition of LM-MEL to CTLA4 is mild, but consistent. In all our studies, this small 
combination effect always occurs. 
IT CDN therapy Conclusions 
We have shown here that IT CDN therapy has powerful effects leading to tumor 
clearance and long term survival of tumor bearing animals. In these studies, we have 
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focused on the innate acute effects of IT CDN therapy while also noting the long term 
adaptive effects that are initiated in the acute phase.  Injection of high dose CDN leads to 
acute and often complete necrosis of the tumor area- an effect that is TNFa dependent. 
Our particular formulation of CDN, a mixed linkage RR-S2 cyclic di-adenosine, binds 
both mouse and human STING forms, though interestingly other CDN formulations we 
have worked with have higher potency at smaller doses in mouse models (unpublished 
data). Similarly, other formulations of CDN and sting agonists have shown differences in 
tumor clearance, induction of cytokines, and activation of an adaptive immune 
response.96  However, we used only the human-binding CDN formulation because this is 
the product that will be taken forward into clinical trials.  Additionally, other groups have 
assessed the use of lower dose CDN and through different vaccination routs to study the 
adaptive response, but that is also not what we focus on here.95,104 The efforts of these 
experiments focused on elucidating the importance and ability of the stromal cell 
compartment to add to effective tumor killing after CDN therapy.  
We firstly showed efficacy and immune phenotype of tumors undergoing this 
therapy. The induction of multiple cytokines including IL-6, TNFa, IFNb, and GM-CSF 
was not surprising because we now understand that signaling downstream of STING 
stimulates both NF-kB and IRF-3 activity. We showed that in the tumor, high dose CDN 
acutely deplete lymphocytic populations, which may necessitate the use of lower doses in 
humans. However, this does does increase the infiltration of neutrophils and 
macrophages, cell subsets that we know can increase inflammation and produce TNFa. In 
the tumor draining lymph node, APC populations greatly increase and become activated, 
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as measured by the presence of CD86. Thus while this dose may not be optimal for 
resident lymphocytes, the potential exists to mount a robust adaptive immune response. 
Importantly, we observe that acute CDN dependent tumor necrosis is not 
dependent on adaptive killing of the tumor, but rather TNFa necrosis alone. Using 
multiple genetic knockout mice, we show that RAG2, IL-6, cGAS, and IFNar are not 
responsible for tumor necrosis. However, STING-/- and TNFa-/- animals fail to show any 
injection site necrosis after IT CDN administration.  
Using a series of bone marrow chimeras, we show that CDN dependent necrosis 
occurs only when host stromal cells are STING competent, and that TNFa can only be 
found in the TME when stromal cells are STING competent. Interestingly, none of our 
results have come in a binary fashion. It has become abundantly clear that the CDN 
dependent immune clearance of tumors depends on cross talk or additive effects of both 
bone marrow and stromal cells. Indeed, both STING-/-WT and WTSTING-/- 
animals experience delayed tumor outgrowth after CDN treatment. Similarly, using a 
series of bone marrow chimeras with TNFa protein knockouts, we showed that both 
WTTNFa-/- and TNFa-/-WT animals show some tumor clearance and injection site 
necrosis. However, bone marrow derived cells seem to be making the majority of TNFa 
because only in animals with TNFa competent bone marrow do we find TNFa in the 
TME.  
We conclude that the tumor stroma is an important factor to consider when 
approaching any tumor therapy, especially those that utilize direct intratumoral injection 
of adjuvant. CDN injection acutely leads to the activation of the stroma, an inflammatory 
immune environment, and tumor clearance. Long term studies will need to be preformed 
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to understand if this inflammatory environment persists, and if this is an ideal 
environment for the priming of adaptive immunity. We also look forward to 
understanding the long term effects of neutrophil and macrophage infiltration into the 
tumor site and into the tumor draining lymph node, because while these subsets are 
acutely inflammatory, it is understood that myeloid subsets can often be, or become 
immune suppressive. However, our observations of activated APC and long term vitiligo 
and dermatitis (unpublished) lead us to believe that these responses do exist and are 
potent, so we propose that IT CDN are a potent tool that represent the successful 
reinvigoration of a concept dating back to William Coley, one of the first men to 
experiment with tumor immunotherapy.  
Drawbacks 
There are several drawbacks of these studies, as indeed there are with any body of 
work. The use of mouse models has been somewhat contentiously debated over the past 
years, and even the use of inbred mice strains has come into question. The basic fact that 
a very small fraction of therapies discovered in mice translate to human clinical trials 
gives scientists pause, rightly so, about the validity and importance of their work. It is, 
however, undeniable that the use of these model systems allows for a greater 
understanding of the human body because small animal systems are manipulatable. 
Knockout animals are indispensable to our field, and indeed we have used many 
genetically modified organisms in these studies. While outbred mice may represent the 
genetic diversity of the human race better than clonal inbred animals, the sample size 
required to do such studies with reasonable scientific precision makes that goal 
unrealistic. Thus, we have chosen mice and indeed mouse tumor models not because we 
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expect absolute fidelity between mice and humans, but because it gave us the ability to 
quickly and thoroughly explore the mechanisms behind tumor clearance and immune 
activation.  
The second drawback of these experiments is the tumor model. While we have 
experimented and shown efficacy of our therapies in multiple models including B16F1 
(melanoma), EL-4 (lymphoma), and CT26 (colon carcinoma), the vast majority of our 
studies have been performed in the highly aggressive and metastatic mouse melanoma 
model B16F10. B16F10 grows at an enormous rate, often killing animals within 3 weeks 
of implantation, depending on the initial implanted tumor burden. This aggressiveness is 
orders of magnitude higher than that observed in any tumor in humans. However, we 
chose this model for several reasons. Firstly, the potency of aCTLA-4 IgG2a is 
staggering. In most models we experimented with, it cures tumors as a single agent. In 
order to discover combinatorial efficacy, we needed an extremely aggressive model. 
Additionally, B16F10 mirrors the efficacy of immunotherapy more closely than many 
models. While the field is advancing, the highest rate of tumor control observed in the 
clinic has been 50-60 percent with PD-1, when patients are binned according to the 
biomarker PD-L1. B16F10 is a vastly uninfiltrated tumor with no truly curative 
immunodominant epitopes and a highly immunosuppressive tumor microenvironment, 
and it is the combination of these factors that makes it representative of the majority of 
fatal tumors in the human population.  
Lastly, the treatment schema for the administration of CDN is not entirely 
representitve of what we expect to be administered in clinical trials. We administered 
100ug of the compound ADU-S100. This is an amount that has been optimized for the 
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clearance of aggressive tumors through the formation of necrosis. We used this dose to 
understand the basis of this necrosis and to understand the ability of different cell types to 
contribute to it. However this dosage, as we have shown, is not optimal for the induction 
of a CD8+ t cell response. It is indeed toxic to TIL acutely. And while this does does 
activate dendritic cells and induce long term immunity, our collaborators at Aduro 
Biotech have shown that lower doses allow for better long term immunity in less 
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